{"id":725,"date":"2020-02-04T08:55:14","date_gmt":"2020-02-04T07:55:14","guid":{"rendered":"http:\/\/invivo.partners\/?post_type=portoflio_invivo&#038;p=725"},"modified":"2021-09-02T12:22:15","modified_gmt":"2021-09-02T10:22:15","slug":"peptomyc","status":"publish","type":"portoflio_invivo","link":"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/","title":{"rendered":"Peptomyc"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Peptomyc es una compa\u00f1\u00eda especializada en el desarrollo de una nueva Peptomyc es una empresa <em>spin-off <\/em>del <strong>Vall d\u00b4Hebron Institute of Oncology<\/strong> (VHIO) e <strong>ICREA<\/strong>. La empresa se centra en el desarrollo de una nueva generaci\u00f3n de p\u00e9ptidos que penetran en las c\u00e9lulas (CPP) dirigidos contra la oncoprote\u00edna Myc para el tratamiento del c\u00e1ncer. El candidato principal, <strong>Omomyc<\/strong>, es un mutante dominante-negativo de Myc en fase cl\u00ednica, que es el inhibidor directo de Myc m\u00e1s eficaz y seguro hasta la fecha y que representa una gran promesa terap\u00e9utica en una variedad de tipos de <strong>c\u00e1ncer<\/strong>.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>CEO y cofundadora: Dra. Laura Soucek<\/li><li>CSO y cofundadora: Dra. Marie-Eve Beaulieu<\/li><li>Ubicaci\u00f3n: Barcelona<\/li><li>P\u00e1gina web: <strong><a rel=\"noreferrer noopener\" href=\"http:\/\/www.peptomyc.com\" target=\"_blank\">peptomyc.com<\/a><\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"featured_media":0,"template":"","tipo_portfolio":[506],"class_list":["post-725","portoflio_invivo","type-portoflio_invivo","status-publish","hentry","tipo_portfolio-healthequity"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Peptomyc - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peptomyc - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Peptomyc es una compa\u00f1\u00eda especializada en el desarrollo de una nueva Peptomyc es una empresa spin-off del Vall d\u00b4Hebron Institute of Oncology (VHIO) e ICREA. La empresa se centra en el desarrollo de una nueva generaci\u00f3n de p\u00e9ptidos que penetran en las c\u00e9lulas (CPP) dirigidos contra la oncoprote\u00edna Myc para el tratamiento del c\u00e1ncer. El\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-02T10:22:15+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/\",\"url\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/\",\"name\":\"Peptomyc - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-02-04T07:55:14+00:00\",\"dateModified\":\"2021-09-02T10:22:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Peptomyc\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Peptomyc - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/","og_locale":"es_ES","og_type":"article","og_title":"Peptomyc - Invivo Partners","og_description":"Peptomyc es una compa\u00f1\u00eda especializada en el desarrollo de una nueva Peptomyc es una empresa spin-off del Vall d\u00b4Hebron Institute of Oncology (VHIO) e ICREA. La empresa se centra en el desarrollo de una nueva generaci\u00f3n de p\u00e9ptidos que penetran en las c\u00e9lulas (CPP) dirigidos contra la oncoprote\u00edna Myc para el tratamiento del c\u00e1ncer. El","og_url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/","og_site_name":"Invivo Partners","article_modified_time":"2021-09-02T10:22:15+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/","url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/","name":"Peptomyc - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-02-04T07:55:14+00:00","dateModified":"2021-09-02T10:22:15+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/peptomyc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/es\/"},{"@type":"ListItem","position":2,"name":"Peptomyc"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo\/725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo"}],"about":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/types\/portoflio_invivo"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/media?parent=725"}],"wp:term":[{"taxonomy":"tipo_portfolio","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/tipo_portfolio?post=725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}